CN101952427A - 产生流感病毒粒子的线性表达构建体 - Google Patents

产生流感病毒粒子的线性表达构建体 Download PDF

Info

Publication number
CN101952427A
CN101952427A CN2008800223549A CN200880022354A CN101952427A CN 101952427 A CN101952427 A CN 101952427A CN 2008800223549 A CN2008800223549 A CN 2008800223549A CN 200880022354 A CN200880022354 A CN 200880022354A CN 101952427 A CN101952427 A CN 101952427A
Authority
CN
China
Prior art keywords
virus
sequence
sections
expression constructs
linear list
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008800223549A
Other languages
English (en)
Chinese (zh)
Inventor
马库斯·沃尔谢克
安德雷杰·埃戈罗夫
迈克尔·伯格曼
托马斯·马斯特
克里斯琴·斯特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Original Assignee
Avir Green Hills Biotechnology Research and Development Trade AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avir Green Hills Biotechnology Research and Development Trade AG filed Critical Avir Green Hills Biotechnology Research and Development Trade AG
Publication of CN101952427A publication Critical patent/CN101952427A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2008800223549A 2007-06-27 2008-06-26 产生流感病毒粒子的线性表达构建体 Pending CN101952427A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94665107P 2007-06-27 2007-06-27
US60/946,651 2007-06-27
EP07450177.6 2007-10-05
EP07450177A EP2045323A1 (en) 2007-10-05 2007-10-05 Linear expression constructs for production of influenza virus particles
PCT/EP2008/058182 WO2009000891A2 (en) 2007-06-27 2008-06-26 Linear expression constructs for production of influenza virus particles

Publications (1)

Publication Number Publication Date
CN101952427A true CN101952427A (zh) 2011-01-19

Family

ID=39099653

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800223549A Pending CN101952427A (zh) 2007-06-27 2008-06-26 产生流感病毒粒子的线性表达构建体

Country Status (9)

Country Link
US (1) US20100129399A1 (cg-RX-API-DMAC7.html)
EP (2) EP2045323A1 (cg-RX-API-DMAC7.html)
CN (1) CN101952427A (cg-RX-API-DMAC7.html)
AU (1) AU2008267180B2 (cg-RX-API-DMAC7.html)
CA (1) CA2689569C (cg-RX-API-DMAC7.html)
EA (1) EA017456B1 (cg-RX-API-DMAC7.html)
IN (1) IN2009KN04355A (cg-RX-API-DMAC7.html)
NZ (1) NZ582102A (cg-RX-API-DMAC7.html)
WO (1) WO2009000891A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091510B2 (en) 2007-03-21 2015-07-28 Schott Corporation Transparent armor system and method of manufacture
EP2072058A1 (en) 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
JP5836266B2 (ja) 2009-05-21 2015-12-24 ノバルティス アーゲー 非内因性polIプロモーターを使用した逆遺伝学
WO2011012999A1 (en) * 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
KR20120083480A (ko) 2009-10-20 2012-07-25 노파르티스 아게 바이러스 구제를 위한 개선된 역유전학 방법
EP2576773A2 (en) * 2010-06-02 2013-04-10 Avir Green Hills Biotechnology Research Development Trade AG Methods and helper viruses for the generation of rna virus
CN102495208B (zh) * 2011-10-24 2014-03-26 山东省农业科学院畜牧兽医研究所 禽流感病毒rt-pcr elisa试剂盒
US10206997B2 (en) * 2011-11-10 2019-02-19 Bin Wang Facilitator-DNA combination vaccine
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
US9708585B2 (en) 2012-12-03 2017-07-18 Seqirus UK Limited Influenza virus reassortment
CA2905612A1 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056914A1 (en) * 1999-03-24 2000-09-28 Gene Therapy Systems, Inc. Method for generating transcriptionally active dna fragments
US20060166321A1 (en) * 2004-11-19 2006-07-27 Yoshihiro Kawaoka Recombinant influenza vectors with tandem transcription units

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288544B6 (sk) * 1998-06-12 2018-03-05 Mount Sinai School Of Medicine Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie
DE69937999T2 (de) * 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
DK1820853T3 (da) * 1999-04-06 2011-12-19 Wisconsin Alumni Res Found Rekombinant influenzavirus til vacciner og genterapi
DE122007000070I1 (de) * 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
AU5921101A (en) * 2000-04-28 2001-11-12 St Jude Childrens Res Hospital Dna transfection system for the generation of infectious influenza virus
CN1678345B (zh) * 2002-04-26 2013-09-11 米迪缪尼有限公司 制备流感病毒的多质粒系统
EP1697521B1 (en) * 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
BRPI0511776B1 (pt) * 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
US8043856B2 (en) * 2007-06-14 2011-10-25 Wisconsin Alumni Research Foundation Adenoviral vectors for influenza virus production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056914A1 (en) * 1999-03-24 2000-09-28 Gene Therapy Systems, Inc. Method for generating transcriptionally active dna fragments
US20060166321A1 (en) * 2004-11-19 2006-07-27 Yoshihiro Kawaoka Recombinant influenza vectors with tandem transcription units

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAKOTO OZAWA等: "An Adenovirus Vector-Mediated Reverse Genetics System for Influenza A Virus Generation", 《JOURNAL OF VIROLOGY》 *

Also Published As

Publication number Publication date
AU2008267180B2 (en) 2014-07-10
US20100129399A1 (en) 2010-05-27
WO2009000891A2 (en) 2008-12-31
NZ582102A (en) 2012-06-29
WO2009000891A3 (en) 2009-02-26
EP2045323A1 (en) 2009-04-08
AU2008267180A1 (en) 2008-12-31
EA017456B1 (ru) 2012-12-28
EP2160462A2 (en) 2010-03-10
CA2689569C (en) 2020-10-27
CA2689569A1 (en) 2008-12-31
EP2160462B1 (en) 2017-07-26
IN2009KN04355A (cg-RX-API-DMAC7.html) 2015-07-10
EA201000076A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
EP2160462B1 (en) Linear constructs for expression of influenza virus
KR101272487B1 (ko) 인플루엔자 바이러스의 구제
US20050037487A1 (en) Recombinant influenza vectors with a PolII promoter and ribozymes for vaccines and gene therapy
US8691238B2 (en) High growth reassortant influenza A virus
US8778357B2 (en) Method for generation of RNA virus
US20130183740A1 (en) Novel method for generation of rna virus
AU2011204881B2 (en) Rescue of influenza virus
HK1153237A (en) Rescue of influenza virus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BAKST HELTH CO., LTD.

Free format text: FORMER OWNER: AVIR GREEN HILLS BIOTECHNOLOGY

Effective date: 20130620

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130620

Address after: Swiss Aupu

Applicant after: Bakst Helth Co., Ltd.

Address before: Austria Vienna

Applicant before: Avir Green Hills Biotechnology

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110119